JNJ vs VRTX: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

Both stocks have similar AI ratings. Review detailed metrics below.

JNJ
JOHNSON & JOHNSON
BUY
86%
Confidence
VS
VRTX
VERTEX PHARMACEUTICALS INC / MA
BUY
86%
Confidence

JNJ vs VRTX Fundamental Comparison

Metric JNJ VRTX
Revenue $94.2B $12.0B
Net Income $26.8B $4.0B
Net Margin 28.5% 32.9%
ROE 32.9% 21.2%
ROA 13.5% 15.4%
Current Ratio 1.03x 2.90x
Debt/Equity 0.51x 0.01x
EPS $11.03 $15.32

Green = Better metric | Red = Weaker metric

View Full JNJ Analysis →
View Full VRTX Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

JNJ vs AAPL VRTX vs MSFT JNJ vs GOOGL VRTX vs AMZN

JNJ vs VRTX: Frequently Asked Questions

Is JNJ or VRTX a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), both stocks have similar ratings. JNJ is rated BUY (86% confidence) while VRTX is rated BUY (86% confidence). This is not investment advice.

How does JNJ compare to VRTX fundamentally?

JOHNSON & JOHNSON has ROE of 32.9% vs VERTEX PHARMACEUTICALS INC / MA's 21.2%. Net margins are 28.5% vs 32.9% respectively.

Which stock pays higher dividends, JNJ or VRTX?

JNJ has a dividend yield of N/A or no dividend while VRTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in JNJ or VRTX for long term?

For long-term investing, consider that JNJ has BUY rating with 86% confidence, while VRTX has BUY rating with 86% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about JNJ vs VRTX?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For JNJ vs VRTX, both AIs rate them similarly based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.